213 related articles for article (PubMed ID: 27803003)
21. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
Mozessohn L; Chan KK; Feld JJ; Hicks LK
J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
Kotake T; Satake H; Okita Y; Hatachi Y; Hamada M; Omiya M; Yasui H; Hashida T; Kaihara S; Inokuma T; Tsuji A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):63-68. PubMed ID: 29984542
[TBL] [Abstract][Full Text] [Related]
23. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
24. Low level of hepatitis B virus screening among patients receiving chemotherapy.
Wi CI; Loo NM; Larson JJ; Moynihan TJ; Madde NR; Grendahl DC; Alberts SR; Kim WR
Clin Gastroenterol Hepatol; 2015 May; 13(5):970-5; quiz e51. PubMed ID: 25460017
[TBL] [Abstract][Full Text] [Related]
25. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases.
Hwang JP; Barbo AG; Perrillo RP
J Viral Hepat; 2015 Mar; 22(3):346-52. PubMed ID: 25220947
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.
Martin ST; Cardwell SM; Nailor MD; Gabardi S
Am J Transplant; 2014 Apr; 14(4):788-96. PubMed ID: 24592928
[TBL] [Abstract][Full Text] [Related]
28. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
[No Abstract] [Full Text] [Related]
29. Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
Hwang JP; Vierling JM; Zelenetz AD; Lackey SC; Loomba R
Support Care Cancer; 2012 Nov; 20(11):2999-3008. PubMed ID: 22933131
[TBL] [Abstract][Full Text] [Related]
30. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan.
Yazaki S; Yamauchi T; Higashi T
Int J Clin Oncol; 2020 Jul; 25(7):1327-1333. PubMed ID: 32200482
[TBL] [Abstract][Full Text] [Related]
31. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
[TBL] [Abstract][Full Text] [Related]
33. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.
Pei SN; Chen CH
Leuk Lymphoma; 2015 Jun; 56(6):1611-8. PubMed ID: 25248874
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
35. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
36. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
[TBL] [Abstract][Full Text] [Related]
38. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Yağci M; Ozkurt ZN; Yeğin ZA; Aki Z; Sucak GT; Haznedar R
Hematology; 2010 Aug; 15(4):240-4. PubMed ID: 20670484
[TBL] [Abstract][Full Text] [Related]
39. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
40. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
